The evaluation of present antileprosy compounds.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D004352:Drug Resistance, Microbial; D005528:Foot; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D051379:Mice; D009113:Muramidase / Q000627:therapeutic use; D009166:Mycobacterium leprae / Q000187:drug effects; D010619:Phenazines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D013828:Thioacetazone / Q000627:therapeutic use; D005719:gamma-Globulins
D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D010619:Phenazines; D013449:Sulfonamides; D013450:Sulfones; D005719:gamma-Globulins; D013792:Thalidomide; D003622:Dapsone; D009113:Muramidase; D013828:Thioacetazone